STUDY INDICATION In relapsed and refractory MM patients, who are progressive, with MM characterized by Deletion 17p or translocation (4;14) Adverse Karyotypic Abnormalities STUDY DESIGN Overall design. This study is a Multicenter, Open-label, Single arm, Phase 2 study of pomalidomide and dexamethasone in relapsed or refractory MM patients with deletion 17p and translocation (4;14). Eligible patients must have a progressive, relapsed or refractory MM, a deletion 17p and/or translocation (4;14) using FISH technique and a measurable disease. There is no escalation dose study, the Maximum Tolerated Dose has already been determined in previous phase 1-2 escalation dose studies as 4 mg/day on day 1 to 21 of a 28 days cycle. The proposed dose of dexamethasone is considered standard. Patients will receive the pomalidomide and dexamethasone regimen until progression. This study will eventually improve time to disease progression and response rates, with no additional toxicity, as compared to other available regimens, in this subgroup of patients with myeloma characterized with an adverse prognosis.